Study: NCT06428045

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT)
Description: Participants will be administered MR-guided Laser Interstitial Thermal Therapy (LITT) as a single procedure, following stereotactic needle biopsy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT)
Description: Participants will be administered MR-guided Laser Interstitial Thermal Therapy (LITT) as a single procedure, following stereotactic needle biopsy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir
Description: Participants will take one 600mg tablet of Abacavir orally once daily, as part of combination antiretroviral therapy (ART).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir
Description: Participants will take one 600mg tablet of Abacavir orally once daily, as part of combination antiretroviral therapy (ART).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Participants will take one 300mg tablet of Lamivudine orally once daily, as part of combination antiretroviral therapy (ART)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Participants will take one 300mg tablet of Lamivudine orally once daily, as part of combination antiretroviral therapy (ART)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Participants will take one tablet of Ritonavir (RTV) orally twice daily, as part of combination antiretroviral therapy (ART), at one of the following dose levels:~* Dose Level -1: 100mg~* Dose Level 1 (starting dose): 300mg~* Dose Level 2: 450mg~* Dose Level 3: 600mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Participants will take one tablet of Ritonavir (RTV) orally twice daily, as part of combination antiretroviral therapy (ART), at one of the following dose levels:~* Dose Level -1: 100mg~* Dose Level 1 (starting dose): 300mg~* Dose Level 2: 450mg~* Dose Level 3: 600mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Participants will take Temozolomide (TMZ) via capsule orally, during and after focal radiotherapy, as part of standard of care adjuvant therapy. During focal radiotherapy, Temozolomide will be administered at a dose of 75 mg/m2 once daily for six weeks (42 days) on a continuous dosing regimen, including weekends and holidays. After completion of focal radiotherapy, Temozolomide will be administered 150-200 mg/m2 on days 1 through 5 of a four-week cycle for a total of six cycles of maintenance therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Participants will take Temozolomide (TMZ) via capsule orally, during and after focal radiotherapy, as part of standard of care adjuvant therapy. During focal radiotherapy, Temozolomide will be administered at a dose of 75 mg/m2 once daily for six weeks (42 days) on a continuous dosing regimen, including weekends and holidays. After completion of focal radiotherapy, Temozolomide will be administered 150-200 mg/m2 on days 1 through 5 of a four-week cycle for a total of six cycles of maintenance therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Focal Radiotherapy
Description: Participants will be administered focal radiotherapy for six weeks (42 days), as part of adjuvant therapy, at a total dose of 50-60 grays (Gy) in 1.8-2.0 Gy fractions, depending on prognosis and as determined by the treating radiation oncologist.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Focal Radiotherapy
Description: Participants will be administered focal radiotherapy for six weeks (42 days), as part of adjuvant therapy, at a total dose of 50-60 grays (Gy) in 1.8-2.0 Gy fractions, depending on prognosis and as determined by the treating radiation oncologist.